Activated CD137 signaling also regulates the expression of NFATc1 and its downstream factors in vascular smooth muscle cells through TRAF6/NF-κB p65 pathways, providing a new target for atherosclerosis treatment. The gene discussed is NFKB1; the disease is atherosclerosis.